Abstract
This article reviews the pharmacological treatment of severely hypoxaemic critically ill patients, notably those with acute respiratory distress syndrome (ARDS), acute lung injury or the sepsis syndrome.
Haemodynamic support in hypotensive patients often initially requires aggressive fluid resuscitation with crystalloids or colloids, combined with vasopressors to maintain adequate end-organ perfusion. The catecholamine of choice in severe hypotension with low systemic resistance is norepinephrine (noradrenaline); dopamine is often used in mild hypotension. Once haemodynamic stabilisation is achieved, loop diuretics such as furosemide (frusemide) are used to obtain the lowest volaemia that guarantees adequate perfusion. If the fraction of inspired oxygen necessary to achieve the satisfactory haemoglobin oxygen saturation of 90% approaches 1, a trial of nitric oxide with or without almitrine is justified. Oxygen consumption can be lowered by treating fever with paracetamol (acetaminophen) and physical cooling. Occasionally, deep sedation using a combination of an opioid (most often morphine or fentanyl) and a benzodiazepine (lorazepam or midazolam) is necessary; in the presence of renal or hepatic insufficiency, propofol is a valid, although expensive, alternative. Paralysis with pancuronium or vecuronium has been associated with critical illness polyneuropathy and is used only as a last resort.
Corticosteroids may be indicated in the subacute (fibroproliferative) phase of ARDS. Other anti-inflammatory treatments (such as cytokine antagonists, cyclooxygenase inhibitors, antioxidants or monoclonal anti-endotoxin antibodies), as well as surfactant supplementation, have failed to improve prognosis in randomised trials.
Article PDF
Similar content being viewed by others
References
Antonelli M, Conti G, Rocco M, et al. A comparison of non-invasive positive-pressure ventilation and conventional mechanical ventilation in patients with acute respiratory failure. N Engl J Med 1998; 339: 429–35
Hyers TM. Adult respiratory distress syndrome: definition, risk factors, and outcome. In: Zapol WM, Lemaire F, editors. Adult respiratory distress syndrome. New York (NY): Dekker, 1991: 23–36
Chabot F, Mitchell JA, Gutteridge JC, et al. Reactive oxygen species in acute lung injury. Eur Respir J 1998; 11: 745–57
Wheeler AP, Bernard GR. Treating patients with severe sepsis. N Engl J Med 1999; 340: 207–14
Bernard GR, Artigas A, Brigham KL, et al. The American-European consensus conference on ARDS: definitions, mechanisms, relevant outcomes, and clinical trial coordination. Am J Respir Crit Care Med 1994; 149: 818–24
Bone RC, Balk RA, Cerra FB, et al. Definitions for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Chest 1992; 101: 1644–55
Schuster DP. Identifying patients with ARDS: time for a different approach. Intensive Care Med 1997; 23: 1197–203
Luce JM. Acute lung injury and the acute respiratory distress syndrome. Crit Care Med 1998; 26: 369–76
Van der Poll T, Lowry SF. Epinephrine inhibits endotoxin-induced IL-1 beta production: roles of tumor necrosis factorα and IL-10. Am J Physiol 1997; 273: R1885–90
Ferring M, Vincent JL. Is outcome from ARDS related to the severity of respiratory failure? Eur Respir J 1997; 10: 1297–300
Abel SJC, Finney SJ, Brett SJ, et al. Reduced mortality in association with the acute respiratory distress syndrome (ARDS). Thorax 1998; 53: 292–4
Franklin C, Samuel J, Hu TC. Life-threatening hypotension associated with emergency intubation and the initiation of mechanical ventilation. Am J Emerg Med 1994; 12: 425–8
Vermeulen LC, Ratko TA, Erstad BL, et al. A paradigm for consensus. The University Hospital Consortium guidelines for the use of albumin, nonprotein colloid, and crystalloid solution. Arch Intern Med 1995; 155: 373–9
Roberts JS, Bratton SL. Colloid volume expanders: problems, pitfalls and possibilities. Drugs 1998; 55: 621–30
Schierhout G, Roberts I. Fluid resuscitation with colloid or crystalloid solutions in critically ill patients: a systematic review of randomised trials. BMJ 1998; 316: 961–4
Margarson MP, Soni N. Serum albumin: touchstone or totem?. Anaesthesia 1998; 53: 789–803
Choi PL, Yip G, Quinonez LG, et al. Crystalloids vs. colloids in fluid resuscitation: a systematic review. Crit Care Med 1999; 27: 200–10
Stockwell MA, Scott A, Day A, et al. Colloid solutions in the critically ill — a randomised comparison of albumin and polygeline 2. Serum albumin concentration and incidences of pulmonary oedema and acute renal failure. Anaesthesia 1992; 47(l): 7–9
Ernest D, Belzberg AS, Dodek PM. Distribution of normal saline and 5% albumin infusions in septic patients. Crit Care Med 1999; 27: 46–50
Boldt J, Muller M, Mentges D, et al. Volume therapy in the critically ill: is there a difference? Intensive Care Med 1998; 24: 28–36
Collis RE, Collins PW, Gutteridge CN, et al. The effect of hydroxyethyl starch and other plasma volume substitutes on endothelial cell activation; an in vitro study. Intensive Care Med 1994; 20: 37–41
Menger MD, Thierjung C, Hammersen F, et al. Dextran vs. hydroxyethylstarch in inhibition of postischemic leukocyte adherence in striated muscle. Circ Shock 1993; 41: 248–55
Boldt J, Heesen M, Welters I, et al. Does the type of volume therapy influence endothelial-related coagulation in the critically ill? Br J Anaesth 1995; 75: 740–6
Marik PE, Iglesias J, Maini B. Gastric intramucosal pH changes after volume replacement with hydroxyethyl starch or crystalloid in patients undergoing elective abdominal aortic aneurysm repair. J Crit Care 1997; 12: 51–5
Warren BB, Durieux ME. Hydroxyethyl starch: safe or not? Anesth Analg 1997; 84: 206–12
Rubin H, Carlson S, DeMeo M, et al. Randomized, double-blind study of intravenous human albumin in hypoalbuminemic patients receiving total parenteral nutrition. Crit Care Med 1997; 25: 249–52
Cochrane Injuries Group Albumin Reviewers. Human albumin administration in critically ill patients: systematic review of randomised controlled trials. BMJ 1998; 317(7153): 235–40
Leibowitz AB. Do pulmonary artery catheters improve patient outcome? No. Crit Care Clin 1996; 12: 559–68
Mitchell JP, Schuller D, Calandrino FS, et al. Improved outcome based on fluid management in critically ill patients requiring pulmonary artery catheterization. Am Rev Respir Dis 1992; 145: 990–8
Jardin F, Valtier B, Beauchet A, et al. Invasive monitoring combined with two-dimensional echocardiographic study in septic shock. Intensive Care Med 1994; 20: 550–4
Cicek S, Demirkilic U, Kuralay E, et al. Prediction of intraoperative hypovolemia in patients with left ventricular hypertrophy: comparison of transesophageal echocardiography and Swan-Ganz monitoring. Echocardiography 1997; 14: 257–60
Taylor RW, Ahrens T, Viejo A, et al. Pulmonary Artery Catheter Consensus Conference: consensus statement. Crit Care Med 1997; 25: 910–25
Hollenberg SM, Ahrens TS, Astiz ME, et al. Practice parameters for hemodynamic support of sepsis in adult patients in sepsis. Crit Care Med 1999; 27: 639–60
Ronco JJ, Fenwick JC, Tweeddale MG, et al. Identification of the critical oxygen delivery for anaerobic metabolism in critically ill septic and nonseptic humans. JAMA 1993; 270: 1724–30
Hayes MA, Timmins AC, Yau EHS, et al. Elevation of systemic oxygen delivery in the treatment of critically ill patients. N Engl J Med 1994; 330: 1717–22
Gattinoni L, Brazzi L, Pelosi P, et al. A trial of goal-oriented hemodynamic therapy in critically ill patients. N Engl J Med 1995; 333: 1025–32
Tuchschmidt J, Fried J, Astiz M, et al. Elevation of cardiac output and oxygen delivery improves outcome in septic shock. Chest 1992; 102: 216–20
Yu M, Burchell S, Hasaniya NA, et al. Relationship of mortality to increasing oxygen delivery in patients > or = 50 years of age: a prospective, randomized trial. Crit Care Med 1998; 26(6): 1011–9
Friedman G, DeBacker D, Shahla M, et al. Oxygen supply dependency can characterize septic shock. Intensive Care Med 1998; 24: 118–23
Shoemaker WC, Appel PL, Kram HB, et al. Prospective trial of supranormal values of survivors as therapeutic goals in high-risk surgical patients. Chest 1988; 94: 1176–86
Boyd O, Grounds RM, Bennett ED. Arandomized clinical trial of the effect of deliberate perioperative increase of oxygen delivery on mortality in high-risk surgical patients. JAMA 1993; 270: 2699–707
Gutierrez G, Palizas F, Doglio G, et al. Gastric intramucosal pH as a therapeutic index of tissue oxygenation in critically ill patients. Lancet 1992; 339: 195–9
Russell JA, Phang PT. The oxygen delivery/consumption controversy: approaches to management of the critically ill. Am J Respir Crit Care Med 1994; 149: 533–7
Riddez L, Hahn RG, Brismar B, et al. Central and regional hemodynamics during acute hypovolemia and volume substitution in volunteers. Crit Care Med 1997; 25: 635–40
Lorente JA, Landin L, Depablo R, et al. Effects of blood transfusion on oxygen transport variables in severe sepsis. Crit Care Med 1993; 21: 1312–8
Marik PE, Sibbald WJ. Effect of stored-blood transfusion on oxygen delivery in patients with sepsis. JAMA 1993; 269: 3024–9
Hebert PC, Wells G, Blajchman M, et al. A multicenter, randomized, controlled clinical trial of transfusion requirements in critical care. N Engl J Med 1999; 340: 409–17
Hebert PC, Wells G, Tweeddale M, et al. Does transfusion practice affect mortality in critically ill patients? Am J Respir Crit Care Med 1997; 155: 1618–23
Stehling LC, Doherty DC, Faust RJ, et al. Practice guidelines for blood component therapy: a report by the American Society of Anesthesiologists Task Force on blood component therapy. Anesthesiology 1996; 84: 732–47
Simon TL, Alverson DC, AuBuchon J, et al. Practice parameter for the use of red blood cell transfusions: developed by the red blood cell administration practice guideline development task force of the college of American pathologists. Arch Pathol Lab Med 1998; 122: 130–8
Martin C, Papazian L, Perrin G, et al. Norepinephrine or dopa-mine for the treatment of hyperdynamic septic shock. Chest 1993; 103: 1826–31
Hoogenberg K, Smit AJ, Girbes AT. Effects of low-dose dopa-mine on renal and systemic hemodynamics during incremental norepinephrine infusion in healthy volunteers. Crit Care Med 1998; 26: 260–5
Juste RN, Panikkar K, Soni N. The effects of low-dose dopa-mine infusions on haemodynamic and renal parameters in patients with septic shock requiring treatment with noradrenaline. Intensive Care Med 1998; 24: 564–8
Duke GJ, Briedis JH, Weaver RA. Renal support in critically ill patients: low-dose dopamine or low-dose dobutamine? Crit Care Med 1994; 22: 1919–25
Juste RN, Moran L, Hooper J, et al. Dopamine clearance in critically ill patients. Intensive Care Med 1998; 24: 1217–20
Marik PE, Mohedin M. The contrasting effects of dopamine and norepinephrine on systemic and splanchnic oxygen utilization in hyperdynamic sepsis. JAMA 1994; 272: 1354–7
Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23: 282–7
Gutierrez G, Clark C, Brown SD, et al. Effect of dobutamine on oxygen consumption and gastric mucosal pH in septic patients. Am J Respir Crit Care Med 1994; 150: 324–9
DeBacker D, Creteur J, Noordally O, et al. Does hepatosplanchnic VO2/DO2 dependency exist in critically ill septic patients? Am J Respir Crit Care Med 1998; 157: 1219–25
Levy B, Bollaert PE, Lucchelli JP, et al. Dobutamine improves the adequacy of gastric mucosal perfusion in epinephrine-treated septic shock. Crit Care Med 1997; 25: 1649–54
Levy B, Bollaert PE, Charpentier C, et al. Comparison of norepinephrine and dobutamine to epinephrine for hemodynamics, lactate metabolism, and gastric tonometric variables in septic shock: a prospective, randomized study. Intensive Care Med 1997; 23: 282–7
Silva E, DeBacker D, Creteur J, et al. Effects of vasoactive drugs on gastric intramucosal pH. Crit Care Med 1998; 26: 1749–58
Marik PE, Varon J. The hemodynamic derangements in sepsis: implications for treatment strategies. Chest 1998; 114: 854–60
Schuller D, Lynch JP, Fine D. Protocol-guided diuretic management: comparison of furosemide by continuous infusion and intermittent bolus. Crit Care Med 1997; 25: 1969–75
Barzilay E, Kessler D, Berlot G, et al. Use of extracorporeal supportive techniques as additional treatment for septic-induced multiple organ failure patients. Crit Care Med 1989; 17: 634–8
Gregory TJ, Longmore WJ, Moxley MA, et al. Surfactant chemical composition and biophysical activity in acute respiratory distress syndrome. J Clin Invest 1991; 88: 1976–81
Gregory TJ, Steinberg KP, Spragg R, et al. Bovine surfactant therapy for patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1997; 155: 1309–15
Weg JG, Balk RA, Tharratt RS, et al. Safety and potential efficacy of an aerosolized surfactant in human sepsis-induced adult respiratory distress syndrome. JAMA 1994; 272: 1433–8
Anzueto A, Baughman RP, Guntupalli KK, et al. Aerosolized surfactant in adults with sepsis-induced acute respiratory distress syndrome. N Engl J Med 1996; 334: 1417–21
Villar J, Blazquez MA, Lubillo S, et al. Pulmonary hypertension in acute respiratory failure. Crit Care Med 1989; 17(6): 523–6
Ignarro LJ, Buga GM, Woods KS, et al. Endothelium-derived relaxing factor produced and released from artery and vein is nitric oxide. Proc Natl Acad Sci USA 1987; 84: 9265–9
Pepke-Zaba J, Higenbottam TW, Dinh-Xuan AT, et al. Inhaled nitric oxide as a cause of selective pulmonary vasodilation in pulmonary hypertension. Lancet 1991; 338: 1173–4
Rossaint R, Falke K, Lopez F, et al. Inhaled nitric oxide in adult respiratory distress syndrome. N Engl J Med 1993; 328: 399–405
Frostell C, Fratacci MD, Wain JC, et al. Inhaled nitric oxide: a selective pulmonary vasodilator reversing hypoxic pulmonary vasoconstriction. Circulation 1991; 83: 2038–47
Gerlach H, Rossaint R, Pappert D, et al. Time-course and dose-response of nitric oxide inhalation for systemic oxygenation and pulmonary hypertension in patients with adult respiratory distress syndrome. Eur J Clin Invest 1993; 23: 499–502
Oda H, Nogami H, Kusumotos S, et al. Long-term exposure to nitric oxide in mice. J Jpn Soc Air Pollut 1976; 11: 150–60
Jörres R, Nowak D, Grimminger F, et al. The effect of 1 ppm nitrogen dioxide on bronchoalveolar lavage cells and inflammatory mediators in normal and asthmatic subjects. Eur Respir J 1995; 8: 416–24
Wennmalm A, Benthin G, Edlund A, et al. Metabolism and excretion on nitric oxide in humans. An experimental and clinical study. Circ Res 1993; 73: 1121–7
Gerlach H, Pappert D, Lewandowski K, et al. Long-term inhalation with evaluated low doses of nitric oxide for selective improvement of oxygenation in patients with adult respiratory distress syndrome. Intensive Care Med 1993; 19: 443–9
Treggiari-Venzi M, Ricou B, Romand JA, et al. The response to repeated nitric oxide inhalation is inconsistent in patients with acute respiratory distress syndrome. Anesthesiology 1998; 88: 634–41
Lavoie A, Hall JB, Olson DM, et al. Life-threatening effects of discontinuing inhaled nitric oxide in severe respiratory failure. Am J Respir Crit Care Med 1996; 153: 1985–7
Jolliet P, Bulpa P, Ritz M, et al. Additive beneficial effects of the prone position, nitric oxide, and almitrine bismesylate on gas exchange and oxygen transport in acute respiratory distress syndrome. Crit Care Med 1997; 25: 786–94
Gallart L, Lu Q, Puy-Basset L, et al. Intravenous almitrine combined with inhaled nitric oxide for acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 158: 1770–7
Doering EB, Hanson CW, Reily DJ, et al. Improvement in oxygenation by phenylephrine and nitric oxide in patients with adult respiratory distress syndrome. Anesthesiology 1997; 87: 18–25
Dellinger RP, Zimmerman JL, Taylor RW, et al. Effects of inhaled nitric oxide in patients with acute respiratory distress syndrome: results of a randomized phase II trial. Crit Care Med 1998; 26: 15–23
Troncy E, Collet JP, Shapiro S, et al. Inhaled nitric oxide in acute respiratory distress syndrome: a pilot randomized controlled study. Am J Respir Crit Care Med 1998; 157: 1483–8
Dinh-Xuan AT, Brunet F, Dhainaut JF. The use, and misuse, of exogenous endothelial-derived vasodilators in acute respiratory failure. Intensive Care Med 1997; 23: 1110–8
Cuthbertson BH, Dellinger P, Dyar OJ, et al. UK guidelines for the use of inhaled nitric oxide therapy in adult ICUs. Intensive Care Medicine 1997; 23: 1212–8
Radermacher P, Santak B, Becker H, et al. Prostaglandin E1 and nitroglycerin reduce pulmonary capillary pressure but worsen ventilation-perfusion distributions in patients with adult respiratory distress syndrome. Anesthesiology 1989; 70: 601–6
Silverman HJ, Slotman G, Bone RC, et al. Effects of prostaglandin E1 on oxygen delivery and consumption in patients with the adult respiratory distress syndrome. Results from the prostaglandin E1 multicenter trial. Chest 1990; 98: 405–10
Abraham E, Park YC, Covington P, et al. Liposomal prostaglandin E(1) in acute respiratory distress syndrome: a placebo-controlled, randomized, double-blind, multicenter clinical trial. Crit Care Med 1996; 24: 10–5
Putensen C, Hörmann C, Kleinsasser A, et al. Cardiopulmonary effects of aerosolized prostaglandin E1 and nitric oxide inhalation in patients with acute respiratory distress syndrome. Am J Respir Crit Care Med 1998; 157: 1743–7
Radermacher P, Santak B, Wust HJ, et al. Prostacyclin for the treatment of pulmonary hypertension in the adult respiratory distress syndrome: effects on pulmonary capillary pressure and ventilation-perfusion distributions. Anesthesiology 1990; 72: 238–44
Zwissler B, Kemming G, Habler O, et al. Inhaled prostacyclin (PGI(2)) versus inhaled nitric oxide in adult respiratory distress syndrome. Am J Respir Crit Care Med 1996; 154: 1671–7
Radermacher P, Buhl R, Santak B, et al. The effects of prostacyclin on gastric intramucosal pH in patients with septic shock. Intensive Care Med 1995; 21: 414–21
Eichelbronner O, Reinelt H, Wiedeck H, et al. Aerosolized prostacyclin and inhaled nitric oxide in septic shock — different effects on splanchnic oxygenation? Intensive Care Med 1996; 22: 880–7
Pittet JF, Lacroix JS, Gunning K, et al. Prostacyclin but not phentolamine increases oxygen consumption and skin microvascular blood flow in patients with sepsis and respiratory failure. Chest 1990; 98: 1467–72
Sibbald WJ, Driedger AA, McCallum D, et al. Nitroprusside infusion does not improve biventricular performance in patients with acute hypoxemic respiratory failure. J Crit Care 1986; 1: 197–203
Melot C, Naeije R, Mols P, et al. Pulmonary vascular tone improves pulmonary gas exchange in adult respiratory distress syndrome. Am Rev Respir Dis 1987; 138: 1232–6
Broseghini C, Brandolese R, Poggi R, et al. Respiratory mechanics during the first day of mechanical ventilation in patients with pulmonary edema and chronic airway obstruction. Am Rev Respir Dis 1988; 138: 355–61
Wright PE, Bernard GR. The role of airflow resistance in patients with the adult respiratory distress syndrome. Am Rev Respir Dis 1989; 139: 1169–74
Wright PE, Carmichael LC, Bernard GR. Effect of bronchodilators on lung mechanics in the acute respiratory distress syndrome (ARDS). Chest 1994; 106: 1517–23
Mancebo J, Amaro P, Lorino H, et al. Effects of albuterol inhalation on the work of breathing during weaning from mechanical ventilation. Am Rev Respir Dis 1991; 144: 95–100
American Association for Respiratory Care. Aerosol consensus statement — 1991. Respir Care 1991; 36: 916–21
Manthous CA, Hall JB, Schmidt GA, et al. Metered-dose inhaler versus nebulized albuterol in mechanically ventilated patients. Am Rev Respir Dis 1993; 148: 1567–70
Bone RC. Toward a theory regarding the pathogenesis of the systemic inflammatory response syndrome: what we do and do not know about cytokine regulation. Crit Care Med 1996; 24: 163–72
Bone RC, Grodzin CJ, Balk RA. Sepsis: a new hypothesis for pathogenesis of the disease process. Chest 1997; 112: 235–43
Bernard GR, Luce JM, Sprung CL, et al. High-dose corticosteroids in patients with the adult respiratory distress syndrome. N Engl J Med 1987; 317: 1565–70
Meduri GU, Headley AS, Golden E, et al. Effect of prolonged methylprednisolone therapy in unresolving acute respiratory distress syndrome: a randomized controlled trial. JAMA 1998; 280: 159–65
Pacht ER, Timerman AP, Lykens MG, et al. Deficiency of alveolar fluid glutathione in patients with sepsis and the adult respiratory distress syndrome. Chest 1991; 100: 1397–403
Suter PM, Domenighetti G, Schaller MD, et al. N-acetylcysteine enhances recovery from acute lung injury in man — a randomized, double-blind, placebo-controlled clinical study. Chest 1994; 105: 190–4
Jepsen S, Herlevsen P, Knudsen P, et al. Antioxidant treatment with N-acetylcysteine during adult respiratory distress syndrome — a prospective, randomized, placebo-controlled study. Crit Care Med 1992; 20: 918–23
Bernard GR, Wheeler AP, Arons MM, et al. A trial of antioxidants N-acetylcysteine and procysteine in ARDS. Chest 1997; 112: 164–72
Domenighetti G, Suter PM, Schaller MD, et al. Treatment with N-acetylcysteine during acute respiratory distress syndrome: a randomized, double-blind, placebo-controlled clinical study. J Crit Care 1997; 12: 177–82
Steinberg SM, Rodriguez JL, Bitzer LG, et al. Indomethacin treatment of human adult respiratory distress syndrome. Circ Shock 1990; 30: 375–84
Montravers P, Fagon JY, Gilbert C. Pilot study of cardiopulmonary risk from pentoxifylline in adult respiratory distress syndrome. Chest 1993; 103: 1017–22
Bacher A, Mayer N, Klimscha W, et al. Effects of pentoxifylline on hemodynamics and oxygenation in septic and nonseptic patients. Crit Care Med 1997; 25: 795–800
Tang WC, Pakula JL, Weil MH, et al. Adrenergic vasopressor agents and mechanical ventilation for the treatment of experimental septic shock. Crit Care Med 1996; 24: 125–30
Bollaert PE, Charpentier C, Levy B, et al. Reversal of late septic shock with supraphysiologic doses of hydrocortisone. Crit Care Med 1998; 26: 645–50
Artigas A, Bernard GR, Carlet J, et al. The American-European Consensus Conference on ARDS, Part 2: ventilatory, pharmacologic, supportive therapy, study design strategies, and issues related to recovery and remodeling. Am J Respir Crit Care Med 1998; 157: 1332–47
Horn KD. Evolving strategies in the treatment of sepsis and systemic inflammatory response syndrome (SIRS). QJM 1998; 91: 265–77
Vincent JL. New therapies in sepsis. Chest 1997; 112: S330–8
Mccloskey RV, Straube RC, Sanders C, et al. Treatment of septic shock with human monoclonal antibody HA-1A: a randomized, double-blind, placebo-controlled trial. Ann Intern Med 1994; 121(1): 1–5
Opal SM, Yu RL. Antiendotoxin strategies for the prevention and treatment of septic shock — new approaches and future directions. Drugs 1998; 55: 497–508
Abraham E, Anzueto A, Gutierrez G, et al. Double-blind randomised controlled trial of monoclonal antibody to human tumour necrosis factor in treatment of septic shock. Lancet 1998; 351: 929–33
Fisher CJ, Dhainaut JFA, Opal SM, et al. Recombinant human interleukin 1 receptor antagonist in the treatment of patients with sepsis syndrome — results from a randomized, double-blind, placebo-controlled trial. JAMA 1994; 271: 1836–43
Dhainaut JFA, Tenaillon A, Letulzo Y, et al. Platelet-activating factor receptor antagonist BN 52021 in the treatment of severe sepsis: a randomized, double-blind, placebo-controlled, multicenter clinical trial. Crit Care Med 1994; 22: 1720–8
Bernard GR, Wheeler AP, Russell JA, et al. The effects of ibuprofen on the physiology and survival of patients with sepsis. N Engl J Med 1997; 336: 912–8
Yu MH, Tomasa G. A double-blind, prospective, randomized trial of ketoconazole, a thromboxane synthetase inhibitor, in the prophylaxis of the adult respiratory distress syndrome. Crit Care Med 1993; 21: 1635–42
Baudo F, Caimi TM, deCataldo F, et al. Antithrombin III (AT III) replacement therapy in patients with sepsis and/or postsurgical complications: a controlled double-blind, randomized, multicenter study. Intensive Care Med 1998; 24: 336–42
van Bommel EFH. Should continuous renal replacement therapy be used for ‘non-renal’ indications in critically ill patients with shock? Resuscitation 1997; 33: 257–70
Rogiers P, Zhang H, Nagler J, et al. Hemofiltration in sepsis and septic shock: where do we stand? Intensivmed 1998; 35: 228–34
Oeda E, Shinohara K, Kamei S, et al. Capillary leak syndrome likely the result of granulocyte colony-stimulating factor after high-dose chemotherapy. Intern Med 1994; 33: 115–9
Wheeler AP. Analgesia, sedation, and therapeutic paralysis in the critically ill. Semin Respir Crit Care Med 1997; 18: 39–63
Shapiro BA, Warren J, Egol AB, et al. Practice parameters for intravenous analgesia and sedation for adult patients in the intensive care unit: an executive summary. Crit Care Med 1995; 23: 1596–600
Boyd O, Grounds M, Bennett D. The dependency of oxygen consumption on oxygen delivery in critically ill postoperative patients is mimicked by variations in sedation. Chest 1992; 101: 1619–24
Manthous CA, Hall JB, Kushner R, et al. The effect of mechanical ventilation on oxygen consumption in critically ill patients. Am J Respir Crit Care Med 1995; 151: 210–4
Marik PE, Kaufman D. The effects of neuromuscular paralysis on systemic and splanchnic oxygen utilization in mechanically ventilated patients. Chest 1996; 109: 1038–42
Freebairn RC, Derrick J, Gomersall CD, et al. Oxygen delivery, oxygen consumption, and gastric intramucosal pH are not improved by a computer-controlled, closed-loop, vecuronium infusion in severe sepsis and septic shock. Crit Care Med 1997; 25: 72–7
Christiansen CL, Ahlburg P, Jakobsen CJ, et al. The influence of propofol and midazolam/halothane anesthesia on hepatic SvO2 and gastric mucosal pH during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1998; 12: 418–21
Poblete B, Romand JA, Pichard C, et al. Metabolic effects of iv propacetamol, metamizol or external cooling in critically ill febrile sedated patients. Br J Anaesth 1997; 78: 123–7
Manthous CA, Hall JB, Olson D, et al. Effect of cooling on oxygen consumption in febrile critically ill patients. Am J Respir Crit Care Med 1995; 151: 10–4
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Elsasser, S., Schächinger, H. & Strobel, W. Adjunctive Drug Treatment in Severe Hypoxic Respiratory Failure. Drugs 58, 429–446 (1999). https://doi.org/10.2165/00003495-199958030-00004
Published:
Issue Date:
DOI: https://doi.org/10.2165/00003495-199958030-00004